NCT07459543 2026-03-09A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In IndiaBristol-Myers SquibbPhase 4 Not yet recruiting30 enrolled